IVIG in myasthenia gravis: Getting enough "bang for the buck"

Neurology

Volumn 68, Issue 11, 2007, Pages 803-804

  Meriggioli, Matthew N ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; PLACEBO;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; EDITORIAL; HUMAN; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT OUTCOME; NOTE;

HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MYASTHENIA GRAVIS;

EID: 34047214672     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000259335.05741.5f     Document Type: Editorial

References (7)

1. Saperstein DS, Barohn RJ. Management of myasthenia gravis. Semin Neurol 2004;24:41-48.
2. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia gravis clinical study group. Ann Neurol 1997;41:789-796.
3. Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25:967-973.
4. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin. Ann Neurol 2005;62:1689-1693.
5. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: A randomized controlled trial. Neurology 2007;68:837-841.
6. Jaretski A, Barohn RJ, Ernstoff H, et al. Myasthenia gravis: recommendations for clinical research standards. Neurology 2000;55:16-23.
7. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Wilson BW. Reliability testing of the quantitative myasthenia gravis score. Ann NY Acad Sci 1998;841:769-772.